21 CFR 1271.75: How do I screen a donor?
Establishments performing donor screening must review donors' relevant medical records for risk factors and clinical evidence of communicable diseases, with added screening by cell type, deem donors with such findings ineligible, and may abbreviate screening for repeat donors within six months.
Part 1271, Human Cells, Tissues, and Cellular and Tissue-Based Products · Subpart C, Donor Eligibility
How FDA words it
The opening lines investigators use most when they cite 1271.75, from the 483s we hold.
Donors were not screened by a review of relevant medical records for risk factors and clinical evidence of communicable disease agents and diseases.Most used
Donors were not screened by a review of relevant medical records for risk factors of communicable disease agents and diseases.1271.75(a)
Cited over time
483s citing 1271.75, by yearMost citations in 2025. Bars are relative to the busiest year. *2026 to date.
Years shown: 2017 to 2026. The busiest year was 2025.
Recent 483s citing 1271.75
- Donor Alliance, Inc. · Denver, ColoradoDonors were not screened by a review of relevant medical records for of… Jan 15, 2026
- Americord Registry LLC · Somerset, New JerseyEMPLOYEE(S> SIGNATURE Donors were not screened by a review of relevant medical… Nov 17, 2025
- Boston IVF Fertility Services at The · Newburgh, IndianaDonors were not screened by a review of relevant medical records for risk factors… Sep 9, 2025
- Johns Hopkins Fertility Center · —Donors were not screened by a review of relevant medical records for risk factors… Aug 14, 2025
- Central Coast Multispecialty Medical · Monterey, CaliforniaDonors were not determined to be ineligible that had risk factors or clinical… May 16, 2025
The regulation text
§ 1271.75 How do I screen a donor?.
(a)All donors. Except as provided under § 1271.90, if you are the establishment that performs donor screening, you must screen a donor of cells or tissue by reviewing the donor's relevant medical records for:
(1)Risk factors for, and clinical evidence of, relevant communicable disease agents and diseases, including:
(i)Human immunodeficiency virus;
(ii)Hepatitis B virus;
(iii)Hepatitis C virus;
(iv)Human transmissible spongiform encephalopathy, including Creutzfeldt-Jakob disease;
(v)Treponema pallidum; and
(2)Communicable disease risks associated with xenotransplantation.
(b)Donors of viable, leukocyte-rich cells or tissue. In addition to the relevant communicable disease agents and diseases for which screening is required under paragraph (a) of this section, and except as provided under § 1271.90, you must screen the donor of viable, leukocyte-rich cells or tissue by reviewing the donor's relevant medical records for risk factors for and clinical evidence of relevant cell-associated communicable disease agents and diseases, including Human T-lymphotropic virus.
(c)Donors of reproductive cells or tissue. In addition to the relevant communicable disease agents and diseases for which screening is required under paragraphs (a) and (b) of this section, as applicable, and except as provided under § 1271.90, you must screen the donor of reproductive cells or tissue by reviewing the donor's relevant medical records for risk factors for and clinical evidence of infection due to relevant communicable diseases of the genitourinary tract. Such screening must include screening for the communicable disease agents listed in paragraphs (c)(1) and (c)(2) of this section. However, if the reproductive cells or tissues are recovered by a method that ensures freedom from contamination of the cells or tissue by infectious disease organisms that may be present in the genitourinary tract, then screening for the communicable disease agents listed in paragraphs (c)(1) and (c)(2) of this section is not required. Communicable disease agents of the genitourinary tract for which you must screen include:
(1)Chlamydia trachomatis; and
(2)Neisseria gonorrhea.
(d)Ineligible donors. You must determine ineligible a donor who is identified as having either of the following:
(1)A risk factor for or clinical evidence of any of the relevant communicable disease agents or diseases for which screening is required under paragraphs (a)(1), (b), or (c) of this section; or
(2)Any communicable disease risk associated with xenotransplantation.
(e)Abbreviated procedure for repeat donors. If you have performed a complete donor screening procedure on a living donor within the previous 6 months, you may use an abbreviated donor screening procedure on repeat donations. The abbreviated procedure must determine and document any changes in the donor's medical history since the previous donation that would make the donor ineligible, including relevant social behavior.
[66 FR 5466, Jan. 19, 2001, as amended at 71 FR 14798, Mar. 24, 2006]
Questions
What does 21 CFR 1271.75 require?
Establishments performing donor screening must review donors' relevant medical records for risk factors and clinical evidence of communicable diseases, with added screening by cell type, deem donors with such findings ineligible, and may abbreviate screening for repeat donors within six months.
How do FDA investigators word a 1271.75 observation?
The most common opening is: “Donors were not screened by a review of relevant medical records for risk factors and clinical evidence of communicable disease agents and diseases.”
Which sections are cited alongside 1271.75?
In the same 483s, investigators most often also cite 1271.47 (What procedures must I establish and maintain?), 1271.50 (How do I determine whether a donor is eligible?), 1271.55 (What records must accompany an HCT/P after the donor-eligibility determination is complete; and what records must I retain?), 1271.160 (Establishment and maintenance of a quality program).